Ku
Kumquat Bio
Cambridge MAFounded 202215 employees
Private CapbiotechPrivateOncology
Platform: T-cell Bio
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Rilufutibatinib | KUM-1527 | NDA/BLA | 2 | CD47 | CRC | ||
| KUM-1252 | KUM-1252 | Preclinical | 1 | Tau | MelanomaCervical Ca | ||
| Zenomavacamten | KUM-6773 | Phase 3 | 1 | CFTR | MS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)